Lonza signs clinical manufacturing deals for two oncology drug candidates

The agreements cover late-stage clinical supply of a monoclonal antibody targeting lymphoma and a small-molecule inhibitor being developed for actinic keratosis.

March 31, 2026

2 min read

View through the trees of Lonza corporate headquarters building in Switzerland

Lonza, a global contract development and manufacturing organization (CDMO) headquartered in Basel, Switzerland, has signed separate manufacturing agreements with ImmuneOncia Therapeutics and Torqur AGs to support late-stage clinical supply of two oncology drug candidates.

Under the agreement with ImmuneOncia, a clinical-stage biopharmaceutical company based in South Korea, Lonza will provide development and clinical manufacturing services for danburstotug, a fully human monoclonal antibody targeting PD-L1 under clinical investigation for relapsed/refractory NK/T-cell lymphoma. Drug substance will be manufactured at Lonza’s Slough, UK site, with drug product development and clinical manufacturing carried out at its Basel and Stein, Switzerland sites, according to the announcement.

In the deal with Torqur, a clinical-stage biotechnology company, Lonza will provide technology transfer, process optimization, and cGMP manufacturing services for bimiralisib, an oral PI3K and mTOR inhibitor that has completed Phase II clinical evaluation for actinic keratosis and is preparing for the next stage of clinical development. Manufacturing will be carried out across Lonza’s highly potent active pharmaceutical ingredient (API) facilities in Nansha, China and Visp, Switzerland.

Heung-Tae Kim, CEO of ImmuneOncia, said in a statement that the company plans to target the rare cancer indication of NK/T-cell lymphoma for early approval, and that the Lonza collaboration is expected to support future global licensing and overseas market entry.

Vladimir Cmiljanovic, CEO of Swiss Rockets, Torqur’s parent company, added in a separate statement that Lonza’s technical expertise and collaborative approach strengthen the foundation needed to advance bimiralisib into late-stage clinical development.

The agreements follow other recent activity at Lonza. Last week, the company launched a media development lab at its Singapore site to help bioprocessing customers optimize cell culture media formulations and reduce scale-up risk ahead of GMP manufacturing.

This piece was created with the help of generative AI tools and edited by our content team for clarity and accuracy.